Details
Stereochemistry | ACHIRAL |
Molecular Formula | C35H52O5S2 |
Molecular Weight | 616.914 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=CC(SC(C)(C)SC2=CC(=C(OC(=O)CCC(O)=O)C(=C2)C(C)(C)C)C(C)(C)C)=CC(=C1O)C(C)(C)C
InChI
InChIKey=RKSMVPNZHBRNNS-UHFFFAOYSA-N
InChI=1S/C35H52O5S2/c1-31(2,3)23-17-21(18-24(29(23)39)32(4,5)6)41-35(13,14)42-22-19-25(33(7,8)9)30(26(20-22)34(10,11)12)40-28(38)16-15-27(36)37/h17-20,39H,15-16H2,1-14H3,(H,36,37)
Succinobucol (also known as AGI-1067) is a probucol derivative patented by American pharmaceutical company Atherogenics, Inc as vascular protectant with antioxidant, anti-inflammatory and antiplatelet activities. In vitro, succinobucol inhibits the TNF-α induced expression of VCAM-1 and MCP-1 with little effect on intercellular adhesion molecule (ICAM)-1. In addition, succinobucol inhibits lipopolysaccharide (LPS)-induced expression of tissue factor in human monocytic cells and endothelial cells, an effect thought to be mediated independently from the nuclear factor κB pathway. Preclinical studies have shown reduced total cholesterol and low-density lipoprotein cholesterol concentrations, increased high-density lipoprotein cholesterol concentrations, decreased levels of inflammatory mediators, and reduced atheroma area with Succinobucol treatment in animal models. Unfortunately, in clinical trials, Succinobucol failed to demonstrate a strong cardioprotective effect. Undesired metabolic effects including high-density lipoprotein cholesterol-lowering have been consistently reported, and diarrhea appears to be an expected adverse effect.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5285 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28435845 |
PubMed
Title | Date | PubMed |
---|---|---|
Drug reverses coronary atherosclerosis. | 2002 Jan 1 |
|
Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies. | 2003 Dec |
|
Effects of AGI-1067 and probucol after percutaneous coronary interventions. | 2003 Feb 4 |
|
Clinical results with AGI-1067: a novel antioxidant vascular protectant. | 2003 Feb 6 |
|
Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. | 2003 Feb 6 |
|
Signal jammer. An academic experiment leads to a new class of drug for attacking heart disease. | 2003 Jul |
|
AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. | 2003 Jun |
|
Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth. | 2003 Nov |
|
Vascular protectants for the treatment of atherosclerosis. | 2003 Sep |
|
Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent. | 2004 Mar |
|
Inhibition of lipoprotein lipid oxidation. | 2005 |
|
Antioxidants and atherosclerosis: emerging drug therapies. | 2005 Feb |
|
Antioxidants: the good, the bad and the ugly. | 2006 Feb |
|
AGI-1067: a novel vascular protectant for prevention of restenosis. | 2006 Jan |
|
Are small biotechs still underselling themselves? | 2006 May |
|
The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease. | 2006 Sep |
|
[Research and developmental strategy of anti-dyslipidemic agents]. | 2007 Apr |
|
Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? | 2007 Apr |
|
Assessment of lipoprotein profiles study (ALPS) and antioxidant activity in healthy subjects treated with AGI-1067. | 2007 Aug |
|
A novel class of antioxidants inhibit LPS induction of tissue factor by selective inhibition of the activation of ASK1 and MAP kinases. | 2007 Aug |
|
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. | 2007 Dec |
|
American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders. | 2007 Jan |
|
Gateways to clinical trials. | 2007 Jan-Feb |
|
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis. | 2007 Jul |
|
Follicular development and expression of the messenger ribonucleic acid for the inhibin/activin subunits in two genetic lines of turkey hens that differ in total egg production. | 2007 May |
|
Pharmacologic approaches to restenosis prevention. | 2007 Sep 3 |
|
Current and emerging paradigms in the therapeutic management of atherosclerosis. | 2008 Dec |
|
Gateways to clinical trials. July-August 2008. | 2008 Jul-Aug |
|
Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. | 2008 Mar |
|
Novel cardiac therapies and innocent by standers. | 2008 May 24 |
|
Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects. | 2009 Apr |
|
Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues. | 2009 Jun |
|
Diabetes treatment. | 2009 Mar |
|
Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy. | 2009 May |
|
Heme oxygenase-1 increases endothelial progenitor cells. | 2009 Oct |
|
Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities. | 2010 |
|
AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. | 2010 Jul 29 |
|
Analyses of copy number variation of GK rat reveal new putative type 2 diabetes susceptibility loci. | 2010 Nov 23 |
|
Probucol and succinobucol in atrial fibrillation: pros and cons. | 2010 Oct 8 |
|
Emerging drugs for hyperlipidemia. | 2010 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00066898
two 150 mg tablets daily with a meal
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C275
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m10272
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | Merck Index | ||
|
J1J54V24R4
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
PP-56
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
DTXSID10176003
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
SUB128140
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
216325
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
216167-82-7
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
100000153841
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
DB05399
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
CHEMBL83626
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
C75299
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
8496
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY | |||
|
C471047
Created by
admin on Sat Dec 16 17:24:28 UTC 2023 , Edited by admin on Sat Dec 16 17:24:28 UTC 2023
|
PRIMARY |
ACTIVE MOIETY